Pharmacotherapy quality analysis for patients with coinfection with HIV / viral hepatitis C (HCV) based on the results of a comprehensive study of ABC/VEN/frequency. A retrospective analysis of prescriptions was based on 62 case histories of patients with HIV/HCV coinfection who were treated at a medical facility (HCF) in Kherson during 2016-2017. A “formal” VEN analysis was carried out based on the National Drug Formulary (NDF) of Ukraine (2016 and 2017) and the Ukrainian clinical guideline on HIV infection in adults and adolescents (2010). When determining the cost of medicines, their prices for 2017 were used according to the Morion Drugs and search system and government procurement prices for antiretroviral drugs. Pharmacotherapy for patients with HIV/HCV coinfection met the basic requirements of the clinical guideline for antiretroviral therapy for HIV infection, but no drugs were prescribed for hepatitis C. According to the results of the ABC/VEN analysis, most of the funds for pharmacotherapy (65.5%) were spent on 90.5% of the drugs included in the NDF, 34.5% of the funds were spent on 9.5% of the drugs that are not included in the NDF, which indicates the need for pharmacotherapy correction in patients. Significant funds for the treatment were spent on a CCR5 receptor inhibitor, Maraviroc (11.84 thousand US dollars for a year of therapy per patient), which currently does not have a sufficient evidence base of effectiveness and was not included in the NDF and clinical protocol. Pharmacotherapy of patients with HIV/HCV needs further correction due to the lack of drugs for the treatment of hepatitis C and the appointment of the expensive drug Maravirok, which was absent in the NDF of Ukraine and the clinical guideline of antiretroviral therapy of HIV infection in adults and adolescents.